Month: May 2024

– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – – Initiated rolling submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Phase 2b ReNeu trial results accepted for oral presentation at the 2024 ASCO Annual Meeting – STAMFORD, Conn., May 02, 2024 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported first quarter financial results for the period ended March 31, 2024 and provided an update on recent company developments. “We are very encouraged by the strong start to the OGSIVEO launch and are focused on continuing...

SUNNYVALE, Calif., May 02, 2024 (GLOBE NEWSWIRE) — eGain (NASDAQ: EGAN), the leading AI knowledge platform for customer service, today announced an online seminar on generative AI for customer service, featuring one of its leading utility clients. “Most AI projects fail. Some estimates place the failure rate as high as 80%—almost double the rate of corporate IT project failures a decade ago,” writes the Harvard Business Review. Businesses are hungry for lessons learned in implementing Generative AI so they can increase their odds of success. The utility client will talk about how they were able to accelerate knowledge building five-fold, while enabling a stellar 98% findability in answers for its contact center agents with eGain’s AI knowledge platform. Attendees will get a unique offer for a no-risk, no-cost production pilot called...

Industry experts join team to position enterprise for growth MIDVALE, Utah, May 02, 2024 (GLOBE NEWSWIRE) — Beyond, Inc. (NYSE:BYON), owner of online retail giants Bed Bath & Beyond, Overstock and Zulily, today announced the addition and appointment of several key leaders to its team:Guncha Mehta, joining as Chief Digital and Information Officer Stacey Shively, joining as Chief Merchandising Officer, Bed Bath & Beyond Angela Minor, joining as Chief Marketing Officer, Bed Bath & Beyond Deb Bollom, appointed to Chief Merchandising Officer, Overstock Steph Whitacre, appointed to SVP GM, Zulily Jennifer Evans, appointed to SVP Marketing, Beyond, Inc. Alexis Callahan, joining as VP of Investor Relations and Public Relations Chris Peake, joining as Director of Merchandising, Zulily“The most important part of building...

Excess Free Cashflow Repayment Pursuant to clause 10.6 Excess Cashflow of the Bonnd agreement the Idavang shall, if and when the aggregate Cash Sweep Amount (relating to the financial years from 2023 and on-wards) is above EUR 8,469,000, apply the Cash Sweep Amount in excess thereof in redemption of the Bonds at a price equal to 102.3925 per cent. of the Nominal Amount redeemed. The redemption will be carried out Pro rata as follows: Excess cashflow amount:                                             EUR 899,000 Redemption price:                                                       102.3925% of the Nominal Amount, plus accrued interest. (However, adjusted according to rounding rules in the CSD) Nominal Amount redeemed:                                         EUR 877,977 Excess Free Cashflow Repayment Date:                         2024-05-08 Record...

Innofactor Plc Managers’ Transactions, on May 2, 2024, at 12:20 Finnish time Innofactor Oyj – Managers’ Transactions ____________________________________________ Person subject to the notification requirementName: Sami EnsioPosition: Chief Executive OfficerIssuer: Innofactor OyjLEI: 7437008OSKQFEDZYD835Notification type: INITIAL NOTIFICATIONReference number: 60904/4/4 ____________________________________________ Transaction date: 2024-05-02Outside a trading venueInstrument type: SHAREISIN: FI0009007637Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 11407 Unit price: 0 EUR Aggregated transactions (1):Volume: 11407 Volume weighted average price: 0 EUR Espoo, May 2, 2024 INNOFACTOR PLC Eija Theis, General Counsel Additional information:Eija Theis, General CounselInnofactor PlcTel....

At the Annual General Meeting of Festi, held on 6 March 2024, the Board of Directors was authorized to approve a share option scheme and to enter into share option agreements with permanent employees of the Group, in compliance with Article 10 of the Income Tax Act No. 90/2003. Share option agreements have now been concluded with employees in accordance with the approved share option scheme. According to the scheme the share option applies to all permanent employees of Festi and its subsidiaries. The purpose of the scheme is to align the interests of the Group’s employees with the performance and long-term goals of the company, and thus the long-term interest of its shareholders. According to the scheme each option holder acquires the right to buy shares in Festi for up to ISK 500,000 once a year for three years, i.e. after the publication...

Innofactor Plc Managers’ Transactions, on May 2, 2024, at 12:20 Finnish time Innofactor Oyj – Managers’ Transactions ____________________________________________ Person subject to the notification requirementName: Anna LindénPosition: Member of the Board/Deputy memberIssuer: Innofactor OyjLEI: 7437008OSKQFEDZYD835Notification type: INITIAL NOTIFICATIONReference number: 60907/4/4 ____________________________________________ Transaction date: 2024-05-02Outside a trading venueInstrument type: SHAREISIN: FI0009007637Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE Transaction details(1): Volume: 22814 Unit price: 0 EUR Aggregated transactions (1):Volume: 22814 Volume weighted average price: 0 EUR Espoo, May 2, 2024 INNOFACTOR PLC Eija Theis, General Counsel Additional information:Eija Theis, General CounselInnofactor...

BEIJING, May 02, 2024 (GLOBE NEWSWIRE) — AirNet Technology Inc., formerly known as AirMedia Group Inc. (“AirNet” or the “Company”) (Nasdaq: ANTE), today announced that it has called an annual general meeting of shareholders (the “AGM”), to be held at Suite 301, No. 26 Dongzhimenwai Street, Chaoyang District, Beijing 100027, People’s Republic of China on May 31, 2024 at 10:00 A.M. (Beijing time). The proposal to be submitted for shareholders’ approval at the AGM is to consider and vote on the resolution to increase the authorized share capital of the Company from US$1,000,000 divided into 22,500,000 ordinary shares of a nominal or par value of US$0.04 each and 2,500,000 preferred shares of a nominal or par value of US$0.04 each to US$40,000,000 divided into 900,000,000 ordinary shares of a nominal or a par value of US$0.04 each...

The company is well in line with the previously presented development plan. Relevant adjustments from previous lab tests have been made, and the company is now fully focused on integrating the driver assistance system BlincVision into vehicles. Part of the integration work involves evaluating sensor placements, adapting communication interfaces to vehicles and optimizing the system for use in a mobile environment. Optimizing sensor placements maximizes efficiency and coverage. The tests also aim to ensure seamless, compatible and reliable communication between BlincVision and the existing systems in the vehicle. Terranet differs from existing solutions on the market through a unique combination of laser scanner, event camera and AI-trained software. The pioneering use of the selected sensor type enables significantly faster identification...

Planegg/Martinsried, May 2, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, announces today that the Company has been issued a patent by the European Patent Office protecting its T cell receptor (TCR) targeting NY-ESO-1 (New York esophageal squamous cell carcinoma 1), a well-recognized and validated cancer-testis antigen, which is expressed in multiple tumor types.  “We are delighted to announce the protection of our NY-ESO-1-targeted TCR in Europe. This TCR, together with the PD1-41BB costimulatory switch protein (CSP), serves as the main component of our lead program MDG1015. This patent grant adds to similar patents that were also granted in the United States, Japan, South Korea, Taiwan...